NCT06774534 SerpinB3 Expression, PAR2 and SCCA-PD Polymorphism in Acute Respiratory Distress Syndrome
| NCT ID | NCT06774534 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Padova |
| Condition | Respiratory Distress Syndrome (RDS) |
| Study Type | OBSERVATIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-02-28 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 40 participants in total. It began in 2025-02-28 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The Acute Respiratory Distress Syndrome (ARDS) is a systemic syndrome characterized by severe respiratory failure, inflammation, loss of aerated tissue and high mortality. Recently, significant efforts have been made to phenotype ARDS patients through a wide range of new biomarkers and imaging indices with the goal of developing personalized treatments based on patient's biophenotypization. Recent literature demonstrates, both in vitro and in vivo but not yet in ARDS patients, that the serine protease inhibitor(SERPIN)-B3 plays a crucial role in the pathological mechanism of pulmonary fibrogenesis, and, similarly, protease-activated receptors(PAR2) is highly involved in this aberrant inflammatory response. Consequently, studying the expression of SERPINB3 (including SCCA-PD polymorphism) and PAR2, in association with a detailed clinical and biomolecular phenotypization, could allow new insights into the pathophysiological mechanisms of lung injury during ARDS.
Eligibility Criteria
Inclusion Criteria: * ARDS DIAGNOSIS * IMV Exclusion Criteria: * Age under 18 years * Pregnancy status * Lack of consent to participate in the study * Contraindications to fiberoptic bronchoscopy and/or BAL (bronchoalveolar lavage) * Patients with chronic inflammatory skin conditions * Patients with chronic lung diseases * Patients with inflammatory respiratory diseases * Patients with neoplasms such as: squamous cell carcinoma of the cervix, squamous cell carcinoma of the esophagus, lung adenocarcinoma, breast adenocarcinoma, pancreatic adenocarcinoma, hepatocellular carcinoma * History of active or passive smoking
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06774534 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Respiratory Distress Syndrome (RDS). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06774534 currently recruiting?
Yes, NCT06774534 is actively recruiting participants. Contact the research team at annalisa.boscolo@gmail.com for enrollment information.
Where is the NCT06774534 trial being conducted?
This trial is being conducted at Padova, Italy.
Who is sponsoring the NCT06774534 clinical trial?
NCT06774534 is sponsored by University of Padova. The trial plans to enroll 40 participants.